The Role of Plant-Derived Natural Products as a Regulator of the Tyrosine Kinase Pathway in the Management of Lung Cancer

QR Code

The Role of Plant-Derived Natural Products as a Regulator of the Tyrosine Kinase Pathway in the Management of Lung Cancer

One of the most common malignant tumors worldwide is lung cancer, and it is associated with the highest death rate among all cancers. Traditional treatment options for lung cancer include radiation, chemotherapy, targeted therapy, and surgical resection. However, the survival rate is low, and the ou...

Full description

Saved in:

Bibliographic Details
Main Authors:	Faris Alrumaihi, Arshad Husain Rahmani, Sitrarasu Vijaya Prabhu, Vikalp Kumar, Shehwaz Anwar
Format:	Article
Language:	English
Published:	MDPI AG 2025-06-01
Series:	Current Issues in Molecular Biology
Subjects:	natural product lung cancer pathogenesis tyrosine kinase tyrosine kinase inhibitors tyrosine-kinase-inhibitor-acquired resistance
Online Access:	https://www.mdpi.com/1467-3045/47/7/498
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Immunomodulating effects of antitumor drugs Bruton tyrosine kinase inhibitors and the possibility of their use in allergic and infectious diseases
by: Yu. S. Torshina, et al.
Published: (2023-06-01)

Establishment of in vitro Src tyrosine kinase inhibitors screening model
by: WANG Chen-hui, et al.
Published: (2007-11-01)

The Mechanisms of Resistance to Tyrosine Kinase Inhibitor Imatinib Therapy of Chronic Myeloid Leukemia
by: S. I. Kutsev, et al.
Published: (2010-06-01)

Cardiovascular and metabolic problems associated with application of second generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia
by: O. Y. Vinogradova
Published: (2015-10-01)

Chronic Myelogenous Leukemia Patients on Tyrosine Kinase Inhibitors—Hematological Changes and Correlation with European Leukemia Network Response Criteria
by: Karthik Bommannan, et al.

Tyrosine Kinase Inhibitors for Gastrointestinal Stromal Tumor After Imatinib Resistance
by: Xian-Hao Xiao, et al.
Published: (2025-07-01)

The Role of STAT5 in Tyrosine Kinase Inhibitor (IMATINIB) Resistance in CML Patients
by: Anastasia Putri, et al.
Published: (2020-02-01)

The Role of STAT5 in Tyrosine Kinase Inhibitor (IMATINIB) Resistance in CML Patients
by: Anastasia Putri, et al.
Published: (2020-02-01)

Dose Optimization of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
by: Chen J, et al.
Published: (2025-07-01)

Ponatinib-induced eruptive squamous cell carcinomas
by: Gabrielle Moore, MBE, MSc, et al.
Published: (2025-08-01)

Tyrosine kinase inhibitors therapy related neutropenia and thrombocythopenia correction in CML patients
by: V. A. Shuvaev, et al.
Published: (2014-07-01)

Innovative Approaches in Cancer Treatment: Emphasizing the Role of Nanomaterials in Tyrosine Kinase Inhibition
by: Antónia Kurillová, et al.
Published: (2025-06-01)

Successful salvage surgery followed by second ALK–TKI after alectinib failure in a patient with ALK-positive NSCLC
by: Hiroshi Hashimoto, et al.
Published: (2022-04-01)

COVID-19 Infection in Chronic Myeloid Leukemia Patients Receiving Tyrosine Kinase Inhibitor in Makassar, Indonesia: A Six-Case Report and Literature Review
by: Tutik Harjianti, et al.
Published: (2023-11-01)

Molecular genetics monitoring of tyrosine kinase inhibitor therapy for chronic myeloid leukemia
by: S. I. Kutsev, et al.
Published: (2022-11-01)

A Possible Association between Deep Molecular Response and Combination of Tyrosine Kinase Inhibitor and Immunochemotherapy in a Patient with Coexisting Chronic Myeloid Leukemia and Follicular Lymphoma: A Case Report
by: Wen-Yung Tsai, et al.
Published: (2025-04-01)

Salvage Pulmonary Resection After Immune Checkpoint or Tyrosine Kinase Inhibitor Therapy for Initially Unresectable Non-Small-Cell Lung Cancer: A Systematic Review
by: Vasile Gaborean, et al.
Published: (2025-06-01)

Nanotechnology-Based Delivery Systems for Enhanced Targeting of Tyrosine Kinase Inhibitors: Exploring Inorganic and Organic Nanoparticles as Targeted Carriers
by: Yana Gvozdeva
Published: (2025-04-01)

Gefitinib: Combination Therapy and Complex Delivery Systems (Review)
by: L. L. Nikolaeva, et al.
Published: (2024-03-01)

Disseminated medullary thyroid carcinoma. Optimal approach to treatment
by: I. S. Romanov, et al.
Published: (2019-01-01)

Treatment Approaches for Diffuse Cutaneous Mastocytosis in Children: Literature Review and Actual Clinical Experience
by: Timur T. Valiev, et al.
Published: (2024-11-01)

Targeted Therapy in a Rare Spindle Cell Tumor with <i>ETV6-NTRK3</i> Gene Fusion Rearrangement: A Case Report
by: Jessé Lopes da Silva, et al.
Published: (2025-01-01)

Early Weight Gain as a Risk Factor for Increased Maximum Weight Gain Among Patients With NSCLC on Lorlatinib and Other ALK Tyrosine Kinase Inhibitors
by: Alexander S. Watson, MD, DPhil, et al.
Published: (2025-09-01)

Recent Advances in the Treatment of Non-small Cell Lung Cancer with Brigatinib
by: Jia YU, et al.
Published: (2025-06-01)

Immunomodulatory role of spleen tyrosine kinase in chronic inflammatory and autoimmune diseases
by: Yaqi Zhou, et al.
Published: (2023-07-01)

Safety of Lorlatinib in Patients with Unresectable Advanced <i>ALK</i>-Positive Non-Small-Cell Lung Cancer Previously Treated with ALK Inhibitors: A Single-Arm, Open-Label, Phase IV Study in India
by: Ullas Batra, et al.
Published: (2025-08-01)

Beyond the Basics: Exploring Pharmacokinetic Interactions and Safety in Tyrosine-Kinase Inhibitor Oral Therapy for Solid Tumors
by: Laura Veronica Budău, et al.
Published: (2025-06-01)

New-generation mutitargeted tyrosine kinase inhibitors in the treatment of radioactive iodine-refractory differentiated thyroid cancer
by: A. M. Mudunov
Published: (2015-06-01)

Chronic myeloid leukemia — before and after imatinib (Third part)
by: E. G. Lomaia, et al.
Published: (2022-11-01)

COVID-19 infection in patients with chronic myeloid leukemia in the Orenburg region during the SARS-CoV-2 pandemic
by: G. B. Kuchma, et al.
Published: (2022-07-01)

Priapism as the first symptom of chronic myeloid leukemia: literature review and own clinical case report
by: T. Yu. Pavlova, et al.
Published: (2022-11-01)

New Paradigm in Treating Cancer: Right on Target
by: Noorwati Sutandyo
Published: (2016-09-01)

New Paradigm in Treating Cancer: Right on Target
by: Noorwati Sutandyo
Published: (2016-09-01)

High-Risk Esophageal GIST: Imaging and Therapeutic Impact on Atypical Metastatic Lesions
by: Predrag Sabljak, et al.
Published: (2025-07-01)

Safety and efficiency of therapy with modern preparations of idiopathic pulmonary fibrosis
by: E. A. Strel’tsov
Published: (2018-03-01)

Precision Enhanced Bioactivity Prediction of Tyrosine Kinase Inhibitors by Integrating Deep Learning and Molecular Fingerprints Towards Cost-Effective and Targeted Cancer Therapy
by: Fatma Hilal Yagin, et al.
Published: (2025-06-01)

Pathological complete response after afatinib treatment of stage IV oligometastatic adenocarcinoma of the lung: the role of pulmonary surgery
by: Ping-Chung Tsai, et al.
Published: (2019-11-01)

Interdisciplinary approach to the management of patients with uterine cancer progression
by: K. Yu. Morkhov, et al.
Published: (2022-05-01)

Efficacy of vandetanib in the treatment of medullary thyroid cancer: literature review and case report
by: А. М. Mudunov, et al.
Published: (2019-10-01)

Historical aspects and modern concepts in the treatment of patients with differentiated thyroid cancer, refractory to radioactive iodine therapy
by: E. V. Borodavina, et al.
Published: (2022-02-01)